KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Revenue (2017 - 2025)

Moderna (MRNA) has disclosed Revenue for 9 consecutive years, with $678.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue fell 41.95% to $678.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 billion, a 42.37% decrease, with the full-year FY2025 number at $1.9 billion, down 39.93% from a year prior.
  • Revenue was $678.0 million for Q4 2025 at Moderna, down from $1.0 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $7.2 billion in Q4 2021 to a low of $108.0 million in Q1 2025.
  • A 5-year average of $2.5 billion and a median of $1.9 billion in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 24112.5% in 2021, then tumbled 92.76% in 2023.
  • Moderna's Revenue stood at $7.2 billion in 2021, then dropped by 29.5% to $5.1 billion in 2022, then plummeted by 44.71% to $2.8 billion in 2023, then crashed by 58.45% to $1.2 billion in 2024, then tumbled by 41.95% to $678.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Revenue are $678.0 million (Q4 2025), $1.0 billion (Q3 2025), and $142.0 million (Q2 2025).